SCHEMBL17961772

SCHEMBL17961772

N#Cc1cnc(N[C@@H]2CCNC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ CHEK1 O14757 6/20 0.46
▸ CCNK O75909 7/20 0.44
▸ CDK12 Q9NYV4 7/20 0.44
▸ CCNT1 O60563 6/20 0.44
▸ CCNE1 P24864 6/20 0.44
▸ CDK2 P24941 6/20 0.44
▸ CDK9 P50750 6/20 0.44
▸ PDPK1 O15530 1/20 0.42
▸ RPS6KB1 P23443 1/20 0.42
▸ CDK7 P50613 2/20 0.41
▸ CCNH P51946 2/20 0.41
▸ MNAT1 P51948 1/20 0.41
▸ HRH4 Q9H3N8 2/20 0.40
▸ HRH3 Q9Y5N1 2/20 0.40
▸ HRH2 P25021 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17961774 1.00 KDM4E (0.46) KDM4EALDH1A1LMNAGAAL3MBTL1
Hydrochloric Acid SCHEMBL23295751 0.98 CHEK1 (0.45) KDM4EALDH1A1LMNAGAAL3MBTL1
Hydrochloric Acid SCHEMBL28546461 0.98 CHEK1 (0.45) KDM4EALDH1A1LMNAGAAL3MBTL1
SCHEMBL29763119 0.90 KDM4E (0.48) KDM4EALDH1A1LMNAGAAL3MBTL1
SCHEMBL17961786 0.86 CCNT1 (0.42) CHEK1CCNKCDK12CCNT1CCNE1
SCHEMBL17961789 0.86 CCNT1 (0.42) CHEK1CCNKCDK12CCNT1CCNE1
Hydrochloric Acid SCHEMBL29777716 0.84 CCNT1 (0.41) CHEK1CCNKCDK12CCNT1CCNE1
SCHEMBL22895560 0.83 HRH4 (0.40) CHEK1RPS6KB1HRH4HRH3HRH2
SCHEMBL28544474 0.81 HRH4 (0.39) CHEK1HRH4HRH3HRH2
SCHEMBL22895799 0.81 HRH4 (0.39) CHEK1HRH4HRH3HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023143482-A1 2-AMINOPYRIMIDINE COMPOUND OR SALT, PREPARATION METHOD THEREFOR AND USE THEREOF 上海辉启生物医药科技有限公司 2023-08-03 — — WO disclosed
EP-3030557-B1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF IDIENCE CO LTD (KR) 2023-05-31 — — EP disclosed
US-RE49338-E1 Phthalazinone derivatives and manufacturing process thereof IDIENCE CO., LTD. (KR) 2022-12-20 — — US disclosed
US-11390618-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2022-07-19 — — US disclosed
US-11358958-B2 — — 2022-06-14 — — US disclosed
US-11358958-B2 — — 2022-06-14 — — US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 — — US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 — — US disclosed
EP-3813819-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2021-05-05 — — EP disclosed
CN-112638373-A Cyclin-dependent kinase inhibitors 金耐特生物制药公司 2021-04-09 — — CN disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 — — US disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 — — US disclosed
US-9844550-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-12-19 — — US disclosed
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2017-06-29 — — US disclosed
US-9682973-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-06-20 — — US disclosed
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2016-08-04 — — US disclosed
CN-105793248-A Novel phthalazinone derivatives and process for preparing the same 日东制药株式会社 2016-07-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof PARP15, PARP10, PARP1 KDM4E 562/4885ALDH1A1 1605/4885LMNA 1070/4885
US-11358958-B2 — CDK2, CDK1, CDK6 KDM4E 1178/4885ALDH1A1 3425/4885LMNA 1011/4885
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 KDM4E 1278/4885ALDH1A1 3722/4885LMNA 1110/4885
US-10894788-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 KDM4E 1278/4885ALDH1A1 3722/4885LMNA 1110/4885
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof PARP15, PARP10, NUDT5 KDM4E 657/4885ALDH1A1 1576/4885LMNA 1157/4885
US-11390618-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 KDM4E 1278/4885ALDH1A1 3722/4885LMNA 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback